Bibliography
- AYALA A, WARTOFSKY L: The case for more aggressive screening and treatment of mild thyroid failure. Cleveland Clin. I Med. (2002) 69:313–320.
- SINGER PA, COOPER DS, LEVY EG et al.: Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA (1995) 273:808–812.
- TOFT AD: Thyroxine therapy. N Engl. Med. (1994) 331:174–180.
- BUNEVICIUS R, KAZANAVICIUS G, ZALINKEVICIUS R, PRANGE AJ JR: Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl. I Med. (1999) 340:424–429.
- MANDEL SJ, BRENT GA, LARSEN PR:Levothyroxine therapy in patients with thyroid disease. Ann. Intern. Med. (1993) 119:492–502.
- ROTI E, MINELLI R, GARDINI E, BRAVERMAN LE: The use and misuse of thyroid hormone. Ent/ea:Me Rev (1993) 14:401–422.
- KAPLAN MM: Thyroid hormone therapy: what, when and how much. Pestgrad. Med. (1993) 93:249–262.
- HENNESSEY JV, BURMAN KD, WARTOFSKY L: The equivalency of two 1-thyroxine preparations. Ann. Intern. Med (1985) 102:770–773.
- DONG BJ, HAUCK WW, GAMBERTOGLIO JG et al.: Bioequivalence of generic and brand levothyroxine products in the treatment of hypothyroidism. JAMA (1997) 277:1205–1213.
- WARTOFSKY L: Bioequivalence of levothyroxine preparations: shortcomings and implications of a recently published study. Endocrinologist (1997) 7:322–33.
- WARTOFSKY L: Bioequivalence of levothyroxine preparations: shortcomings and implications of a recently published study. Letters to Editor incl. Dong, B. et al.: Endocrinologist (1998) 8:149–151. (1999) 9:1.
- GUIDANCE FOR INDUSTRY: Levothyroxine sodium products enforcement of August 14, 2001. Compliance date and submission of new applications. US Food and Drug Administration. July 2001.
- ••The landmark FDA publication declaringthat all levothyroxine products were new drugs and that either a NDA or a citizen's petition proving safety and efficacy was required in order for manufacturers to continue to market their levothyroxine product.
- SCHALL R, WILLIAMS RL: Towards a practical strategy for assessing individual bioequivalence. (FDA Working Panel) Pharmacakin. Biapharmaceur (1996) 24:133–149.